Whereas this semaglutide tablet is the primary to deal with weight problems, it isn’t the primary that Novo Nordisk has made. The corporate’s scientists first grew to become fascinated about semaglutide as a diabetes therapy since it will probably additionally assist management blood glucose, and its first semaglutide-based remedy, Ozempic, was permitted in 2017 for diabetes. Sufferers injected themselves as soon as per week to manage blood sugar, however to make taking the drug simpler, the corporate additionally developed a tablet kind, referred to as Rybelsus, which the FDA permitted in 2019. Turning Ozempic into an oral tablet required discovering a strategy to defend the drug from the hostile surroundings of the abdomen simply lengthy sufficient for it to be absorbed by the physique. “However with numerous these methods, it could trigger an excessive amount of permeability—so issues that shouldn’t be absorbed, like micro organism or different issues, had been absorbed,” says Andrea Traina, senior medical director for weight problems and liver well being at Novo Nordisk. The scientists finally discovered a strategy to create a chemical buffer to defend the drug whereas it launched sufficient semaglutide to be efficient. Nonetheless, as a result of the tablet has to undergo the abdomen and digestive tract, it’s typically not as efficient because the injected Ozempic.
Support Greater and Subscribe to view content
This is premium stuff. Subscribe to read the entire article.
